The complete neuroendocrine satiety system involves gut peptides (GLP-1, PYY, CCK, oxyntomodulin, ghrelin), enteric neural signaling, and central integration — with gut peptide-based drugs as the most promising obesity pharmacotherapy.
Key findingGI neuroendocrine satiety regulation integrates gut peptide signals (GLP-1, PYY, CCK, oxyntomodulin, ghrelin), enteric neural pathways, and central me
What the researchers found
GI neuroendocrine satiety regulation integrates gut peptide signals (GLP-1, PYY, CCK, oxyntomodulin, ghrelin), enteric neural pathways, and central melanocortin/NPY circuits for comprehensive food intake control — gut peptide drugs leading the obesity treatment pipeline.
Why it matters
Relevant for neuropeptides, glp-1, weight-loss.
How the study worked
review study on neuropeptides, glp-1.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2007.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Review article: The gastrointestinal tract: neuroendocrine regulation of satiety and food intake.
Alimentary pharmacology & therapeutics, 26 Suppl 2, 241-50
Citation
Maljaars, J; Peters, H P F; Masclee, A M. (2007). Review article: The gastrointestinal tract: neuroendocrine regulation of satiety and food intake.. Alimentary pharmacology & therapeutics, 26 Suppl 2, 241-50. https://doi.org/10.1111/j.1365-2036.2007.03550.x